Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.

Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J; TUGAMO GROUP.

Br J Cancer. 2013 Jul 9;109(1):121-30. doi: 10.1038/bjc.2013.272. Epub 2013 Jun 25.

2.

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.

de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J.

Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30.

3.

Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases.

López-Carrizosa MC, Samper-Ots PM, Pérez AR.

Clin Transl Oncol. 2010 Aug;12(8):568-73. doi: 10.1007/s12094-010-0555-z.

PMID:
20709654
4.

[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].

Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Jun;30(6):1343-6. Chinese.

5.

Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.

Søe K, Delaissé JM, Jakobsen EH, Hansen CT, Plesner T.

Acta Oncol. 2014 Apr;53(4):547-56. doi: 10.3109/0284186X.2013.844358. Epub 2013 Oct 28.

PMID:
24164102
6.

Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.

Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K.

Eur Urol. 2007 Nov;52(5):1381-7. Epub 2007 Feb 20.

PMID:
17321667
7.

Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.

Mountzios G, Terpos E, Syrigos K, Papadimitriou C, Papadopoulos G, Bamias A, Mavrikakis M, Dimopoulos MA.

Transl Res. 2010 May;155(5):247-55. doi: 10.1016/j.trsl.2010.01.002.

PMID:
20403580
8.
9.

Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.

Aktas B, Kasimir-Bauer S, Lehmann N, Kimmig R, Tewes M.

Oncol Rep. 2013 Jul;30(1):441-7. doi: 10.3892/or.2013.2409. Epub 2013 Apr 22.

PMID:
23604361
10.

Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O'Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP.

Clin Genitourin Cancer. 2015 Feb;13(1):50-8. doi: 10.1016/j.clgc.2014.07.002. Epub 2014 Jul 15.

PMID:
25163397
11.

Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.

Rief H, Omlor G, Akbar M, Bruckner T, Rieken S, Förster R, Schlampp I, Welzel T, Bostel T, Roth HJ, Debus J.

BMC Cancer. 2016 Mar 17;16:231. doi: 10.1186/s12885-016-2278-1.

12.

Bone remodeling markers in the detection of bone metastases in prostate cancer.

de la Piedra C, Castro-Errecaborde NA, Traba ML, Méndez-Dávila C, García-Moreno C, Rodriguez de Acuña L, Rodriguez-Molina J.

Clin Chim Acta. 2003 May;331(1-2):45-53.

PMID:
12691863
13.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
14.

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.

Ann Oncol. 2007 Jul;18(7):1165-71. Epub 2007 Apr 17. Erratum in: Ann Oncol. 2008 Mar;19(3):601.

PMID:
17442659
16.

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE.

J Natl Cancer Inst. 2005 Jan 5;97(1):59-69.

PMID:
15632381
17.

Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.

Tunn UW, Stenzl A, Schultze-Seemann W, Strauss A, Kindler M, Miller K, Wirth MP, Zantl N, Schulze M, May C, Ruebel A, Birkholz K, Gruenwald V.

Can J Urol. 2012 Jun;19(3):6261-7.

PMID:
22704310
18.

Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.

Izumi K, Mizokami A, Itai S, Shima T, Shigehara K, Miwa S, Maeda Y, Konaka H, Koh E, Namiki M.

BJU Int. 2012 Feb;109(3):394-400. doi: 10.1111/j.1464-410X.2011.10192.x. Epub 2011 May 23.

19.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.

J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.

20.

Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.

Saad F, Eastham JA.

Semin Oncol. 2010 Jun;37 Suppl 1:S38-44. doi: 10.1053/j.seminoncol.2010.06.001. Review.

PMID:
20682371

Supplemental Content

Support Center